Kerstin N Vokinger

Publication Activity (10 Years)

Years Active: 2021-2023
Publications (10 Years): 9

Top Topics

Cross Sectional

Decision Making

Top Venues

JCO oncology practice

Nature medicine

Nature reviews. Clinical oncology

This page only lists publications with an associated author ORCID identifier.

Publications

Kerstin N Vokinger, Miquel Serra-Burriel, Camille E G Glaus, Ulrich-Peter Rohr, Thomas J Hwang, Simon Andreas Dalla Torre di Sanguinetto, Aaron S Kesselheim
Regulatory Review Duration and Differences in Submission Times of Drugs in the United States and Europe, 2011 to 2020. Annals of internal medicine 176 (10) (2023)
Camille E G Glaus, Andrina Kloeti, Kerstin N Vokinger
Defining 'therapeutic value' of medicines: a scoping review. BMJ open 13 (12) (2023)
Camille E G Glaus, Andrina Kloeti, Kerstin N Vokinger
Defining 'therapeutic value' of medicines: a scoping review. BMJ open 13 (12) (2023)
Camille E G Glaus, Andrina Kloeti, Kerstin N Vokinger
Defining 'therapeutic value' of medicines: a scoping review. BMJ open 13 (12) (2023)
Kerstin N Vokinger, Camille E G Glaus, Aaron S Kesselheim, Miquel Serra-Burriel, Joseph S Ross, Thomas J Hwang
Therapeutic value of first versus supplemental indications of drugs in US and Europe (2011-20): retrospective cohort study. BMJ (Clinical research ed.) 382 (2023)
Camille E G Glaus, Andrina Kloeti, Kerstin N Vokinger
Defining 'therapeutic value' of medicines: a scoping review. BMJ open 13 (12) (2023)
Thomas J Hwang, Aaron S Kesselheim, Ariadna Tibau, ChangWon C Lee, Kerstin N Vokinger
Clinical Benefit and Expedited Approval of Cancer Drugs in the United States, European Union, Switzerland, Japan, Canada, and Australia. JCO oncology practice 18 (9) (2022)
Melissa Newham, Kerstin N Vokinger
Adverse effects of acquisitions in the pharmaceutical industry. Nature medicine 28 (7) (2022)
Kerstin N Vokinger, Aaron S Kesselheim
Value-based pricing of drugs with multiple indications or in combinations - lessons from Europe. Nature reviews. Clinical oncology (2021)